Cardiac health in women with metabolic syndrome: clinical aspects and pathophysiology.
Although the classical cardiovascular risk factors (e.g., smoking and hypertension) are becoming more effectively managed, a continuous increase of the so-called "cardiometabolic risk" is noted. Starting from this century, the nomenclature "metabolic syndrome" has become more popular to identify a cluster of disorders including obesity, dyslipidemia, hypertension, and insulin resistance. It is a primary risk factor for diabetes and cardiovascular disease in both genders. Interestingly, the metabolic diseases display a distinct gender disparity with an apparent "female advantage" in the premenopausal women compared with age-matched men. However, women usually lose such "sex protection" following menopause or affliction of metabolic syndrome especially insulin resistance. A controversy exists in the medical literature concerning whether metabolic syndrome is a real syndrome or simply a cluster of risk factors. Several scenarios are speculated to contribute to the gender dimorphism in the cardiovascular sequelae in patients with metabolic syndrome including sex hormones, intrinsic organ function, and the risk factor profile (e.g., hypertension, dyslipidemia, obesity, sedentary lifestyle, and atherogenic diet). With the alarming rise of obesity prevalence, heart problems in metabolic syndrome continue to rise with a distinct gender dimorphism. Although female hearts seem to better tolerate the stress insults compared with the male counterparts, the female sex hormones such as estrogen can interact with certain risk factors to precipitate myopathic changes in the hearts. This synthetic review of recent literature suggests a role of gender disparity in myopathic factors and risk attributable to each metabolic component in the different prevalence of metabolic syndrome.
Ren
Jun
J
University of Wyoming College of Health Sciences, Laramie, Wyoming, USA. jren@uwyo.edu
Kelley
Robert O
RO
D054392:Adipokines / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism; D004730:Endothelium, Vascular / Q000378:metabolism; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D012739:Gonadal Steroid Hormones / Q000378:metabolism; D006331:Heart Diseases / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control; D006706:Homeostasis; D006801:Humans; D007249:Inflammation / Q000150:complications; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications* / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D009206:Myocardium / Q000378:metabolism; D015995:Prevalence; D018570:Risk Assessment; D012307:Risk Factors; D012737:Sex Factors; D016387:Women's Health
D054392:Adipokines; D001786:Blood Glucose; D012739:Gonadal Steroid Hormones; D008055:Lipids